144 related articles for article (PubMed ID: 34708270)
1. Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies.
Bagepally BS; Sasidharan A
Eur J Clin Pharmacol; 2022 Mar; 78(3):351-363. PubMed ID: 34708270
[TBL] [Abstract][Full Text] [Related]
2. Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression.
Rivera FB; Cha SW; Magalong JV; Bantayan NRB; Cruz LLA; Arias-Aguirre E; Aguirre Z; Varona MC; Co EMF; Lumbang GNO; Enkhmaa B
Curr Med Res Opin; 2024 Jul; 40(7):1103-1121. PubMed ID: 38836510
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias' treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network metaanalysis.
Pamporis K; Karakasis P; Simantiris S; Sagris M; Bougioukas KI; Fragakis N; Tousoulis D
Clin Investig Arterioscler; 2024; 36(2):86-100. PubMed ID: 38040529
[TBL] [Abstract][Full Text] [Related]
4. Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review.
McClintick DJ; Giugliano RP
Curr Opin Lipidol; 2023 Dec; 34(6):243-251. PubMed ID: 37606894
[TBL] [Abstract][Full Text] [Related]
5. Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings.
Muntner P; Ghazi L; Jones J; Dhalwani N; Poudel B; Wen Y; Chen L; Wang Z; Bittner V; Kalich B; Farkouh ME; Woodward M; Colantonio LD; Rosenson RS
Adv Ther; 2024 Jun; 41(6):2399-2413. PubMed ID: 38691317
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors After Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials.
Atia A; Aboeldahab H; Wageeh A; Elneny M; Elmallahy M; Elawfi B; Aboelkhier MM; Elrosasy A; Abdelwahab MM; Sayed S; Abdelaziz A
Am J Cardiovasc Drugs; 2024 Jan; 24(1):83-102. PubMed ID: 38241002
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of tumor necrosis factor-alpha inhibitors: a systematic review and meta-analysis of cost-utility studies.
Kumar S; Bagepally BS
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(9):1027-1040. PubMed ID: 37604704
[TBL] [Abstract][Full Text] [Related]
8. Flexible Approaches Based on Multistate Models and Microsimulation to Perform Real-World Cost-Effectiveness Analyses: An Application to Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors.
Gregorio C; Rea F; Ieva F; Scagnetto A; Indennidate C; Cappelletto C; Di Lenarda A; Barbati G
Value Health; 2024 Jul; 27(7):897-906. PubMed ID: 38548178
[TBL] [Abstract][Full Text] [Related]
9. Impact of national drug price negotiation policy on the accessibility and utilization of PCSK9 inhibitors in China: an interrupted time series analysis.
Zhang L; Wang X; Yao H; Ding B; Gao X; Li X
Int J Equity Health; 2024 Jun; 23(1):116. PubMed ID: 38840134
[TBL] [Abstract][Full Text] [Related]
10. Lipid lowering for prevention of venous thromboembolism: a network meta-analysis.
Farmakis IT; Christodoulou KC; Hobohm L; Konstantinides SV; Valerio L
Eur Heart J; 2024 Jun; ():. PubMed ID: 38874212
[TBL] [Abstract][Full Text] [Related]
11. PCSK9 Inhibitors and Infection-Related Adverse Events: A Pharmacovigilance Study Using the World Health Organization VigiBase.
Park D; Bea S; Bae JH; Lee H; Choe YJ; Shin JY; Kim H
Drugs Real World Outcomes; 2024 Jul; ():. PubMed ID: 38954190
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of interventions for the prevention and control of COVID-19: Systematic review of 85 modelling studies.
Zhou L; Yan W; Li S; Yang H; Zhang X; Lu W; Liu J; Wang Y
J Glob Health; 2022 Jun; 12():05022. PubMed ID: 35712857
[TBL] [Abstract][Full Text] [Related]
13. PCSK9 inhibition and broad health outcomes: A Mendelian randomization phenome‑wide association study.
Zhang K; Bian Q
Pharmacol Res; 2024 May; 203():107177. PubMed ID: 38604294
[No Abstract] [Full Text] [Related]
14. The potential future role of extensive lipid lowering in ACS patients with the use of PCSK9 inhibitors: early bird catches the worm.
Dimitriadis K; Pyrpyris N; Tsioufis K
Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):85-86. PubMed ID: 37977850
[No Abstract] [Full Text] [Related]
15. Mapping the value for money of precision medicine: a systematic literature review and meta-analysis.
Chen W; Wong NCB; Wang Y; Zemlyanska Y; Butani D; Virabhak S; Matchar DB; Prapinvanich T; Teerawattananon Y
Front Public Health; 2023; 11():1151504. PubMed ID: 38074712
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic adherence in patients treated with PCSK9i: focus on skin side effects.
Dal Pino B; Sbrana F
Acta Cardiol; 2024 Feb; ():1-2. PubMed ID: 38334104
[No Abstract] [Full Text] [Related]
17. PCSK9 Inhibition-Based Therapeutic Approaches: An Immunotherapy Perspective.
Momtazi-Borojeni AA; Pirro M; Xu S; Sahebkar A
Curr Med Chem; 2022; 29(6):980-999. PubMed ID: 34711156
[TBL] [Abstract][Full Text] [Related]
18. Genetics, Safety, Cost-Effectiveness, and Accessibility of Injectable Lipid-Lowering Agents: A Narrative Review.
Sindi AAA
J Lipids; 2023; 2023():2025490. PubMed ID: 36935878
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia.
Ge X; Zhu T; Zeng H; Yu X; Li J; Xie S; Wan J; Yang H; Huang K; Zhang W
Biomed Res Int; 2021; 2021():8032978. PubMed ID: 34754882
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
Michaeli DT; Michaeli JC; Boch T; Michaeli T
Clin Drug Investig; 2022 Aug; 42(8):643-656. PubMed ID: 35819632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
